Ruxolitinib

Generic Name: Ruxolitinib

Brand Names: Jakafi, Jakavi, Opzelura

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈N_₆

CAS Number: 941678-49-5

Unique Ingredient Identifier: 82S8X8XX8H

Background: Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...

Indication: Ruxolitinib is indicated for the treatment of the following conditions:

Topical ruxolitinib is indicated for:

Associated Conditions: Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera

Associated Therapies: -

Clinical Trials

Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy

Conditions: Myelofibrosis

First Posted Date: 2019-05-22

Last Posted Date: 2019-05-22

Lead Sponsor: Margherita Maffioli

Target Recruit Count: 620

Registration Number: NCT03959371

Locations: 🇮🇹
U.O. Ematologia, ASST Spedali Civili, Brescia, Italy
🇮🇹
Clinica Ematologica, Ospedale San Gerardo, Monza, Italy
🇮🇹
U.O.C. di Ematologia Clinica, ASST Lecco, Lecco, Italy

and more 9 locations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat

First Posted Date: 2019-03-18

Last Posted Date: 2024-03-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03878524

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Phase 1

Recruiting

Conditions: Essential Thrombocythemia
Myelofibrosis
Myeloproliferative Neoplasm
Polycythemia Vera
Secondary Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Drug: Ruxolitinib

First Posted Date: 2019-03-18

Last Posted Date: 2024-04-15

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 47

Registration Number: NCT03878199

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Simmons Cancer Center, Dallas, Texas, United States
🇺🇸
OHSU, Portland, Oregon, United States

Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Suspended

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia

Interventions: Drug: Ruxolitinib
Drug: Venetoclax

First Posted Date: 2019-03-14

Last Posted Date: 2024-08-19

Lead Sponsor: Brian Druker

Target Recruit Count: 50

Registration Number: NCT03874052

Locations: 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Ruxolitinib in Treating Patients with Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Phase 2

Recruiting

Conditions: Blasts 20 Percent or Less of Peripheral Blood White Cells
Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
Hepatomegaly
Blasts Under 20 Percent of Bone Marrow Nucleated Cells
Chronic Eosinophilic Leukemia, Not Otherwise Specified
Hypereosinophilic Syndrome
BCR-JAK2 Fusion Protein Expression
Eosinophilia
TEL-JAK2 Fusion Protein Expression
Blasts More Than 5 Percent of Peripheral Blood White Cells

Interventions: Drug: Ruxolitinib

First Posted Date: 2019-01-11

Last Posted Date: 2024-12-20

Lead Sponsor: William Shomali

Target Recruit Count: 10

Registration Number: NCT03801434

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸
Fred Hutchinson cancer research center, Seattle, Washington, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

and more 1 locations

Ruxolitinib Combined With Dexamethasone for HLH

Phase 1

Conditions: Hemophagocytic Lymphohistiocytosis

Interventions: Drug: Ruxolitinib
Drug: Dexamethasone

First Posted Date: 2019-01-08

Last Posted Date: 2019-01-08

Lead Sponsor: Capital Research Institute of Pediatrics

Target Recruit Count: 50

Registration Number: NCT03795909

Locations: 🇨🇳
Yan Yue, Beijing, China

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Ruxolitinib
Drug: Dexamethasone

First Posted Date: 2018-12-12

Last Posted Date: 2024-08-16

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 12

Registration Number: NCT03773107

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Phase 2

Active, not recruiting

Conditions: Leukemia
Chronic Myelomonocytic Leukemia

Interventions: Drug: Ruxolitinib

First Posted Date: 2018-10-29

Last Posted Date: 2024-12-12

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 29

Registration Number: NCT03722407

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

and more 2 locations

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Ruxolitinib
Drug: Nivolumab

First Posted Date: 2018-09-24

Last Posted Date: 2024-10-21

Lead Sponsor: Veronika Bachanova

Target Recruit Count: 54

Registration Number: NCT03681561

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States

and more 2 locations

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Phase 2

Active, not recruiting

Conditions: Other Cancer

Interventions: Drug: ruxolitinib

First Posted Date: 2018-09-17

Last Posted Date: 2024-03-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT03674047

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy